Abstract Background and aims: During the past three decades the relationship between habitual coffee drinking and coronary heart disease (CHD) has been assessed in numerous studies, with conflicting results. The aim of this study was to systematically examine the data published on the association between habitual coffee consumption and risk of CHD. Methods and results: Thirteen caseecontrol and 10 cohort studies were included. Caseecontrol studies incorporated 9487 cases of CHD and 27,747 controls, and cohort studies included a total of 403,631 participants that were followed for between 3 and 44 years. The summary of odds ratios (OR) for the caseecontrol studies showed statistically significant associations between coffee consumption and CHD for the highest intake group (>4 cups/day), OR 1.83 (95% CI 1.49e2.24; P < 0.0001), and for the second highest category (3e4 cups/day), OR 1.33 (95% CI 1.04e1.71; P < 0.0001), while no significant association emerged for low daily coffee intake (2 cups/day), OR 1.03 (95% CI 0.87e1.21; P ¼ 0.45). The analysis of long-term follow-up cohort studies did not show any association between the consumption of coffee and CHD, with a relative risk (RR) of 1.16 (95% CI 0.95e1.41; P ¼ 0.14) for the highest category, and 1.05 (95% CI 0.90e1.22; P ¼ 0.57) and www.elsevier.com/locate/nmcd 1.04 (95% CI 0.90e1.19; P ¼ 0.60) for the second and third highest categories, respectively. These results did not differ substantially when controlling for region of origin, fatal and non-fatal events, year of publication, and number of years of follow-up. Conclusions: Despite a significant association between high consumption of coffee and CHD reported among caseecontrol studies, no significant association between daily coffee consumption and CHD emerged from long-term follow-up prospective cohort studies. ª
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Introduction
Coffee is one of the most widely consumed beverages in the world. Since early 1970s, coffee consumption has attracted interest as a potential health hazard due to the positive association with coronary heart disease (CHD) reported in a number of caseecontrol and cohort studies [1e14] . However, in contrast with these results, other caseecontrol and cohort studies performed in different population groups showed negative results, perhaps indicating that in some of the previous studies the strong association reported between coffee consumption and CHD resulted from inappropriate statistical analysis, i.e. lack of adjustment for possible confounders [15e28] .
To date, the question whether coffee drinking increases the risk of CHD continues to be controversial. Meta-analyses of the association between coffee consumption and CHD carried out in the 1990s reported conflicting results within the different types of studies analysed, as shown by the positive association with CHD found among caseecontrol but not among cohort studies. In 1992, Myers and Babinski carried out a metaanalysis of cohort prospective studies and reported no influence of coffee on CHD [29] ; whereas in 1993, Greenland reported a positive association with CHD among caseecontrol studies, but not among prospective cohort studies [30] . The latter association is supported by the most recent analysis conducted in 1994 by Kawachi et al., which showed an increased risk of CHD with consumption of five cups of coffee per day, but only among caseecontrol studies [31] .
Currently, the influence of coffee on the health of people, is considered of great significance due to the enormous consumption worldwide. However, analysing the occurrence of disease in relation to intake of coffee is difficult, mainly due to the complexities that arise when trying to define a coffee beverage. Coffee, as a beverage made from the extract of coffee beans, is available in a remarkable variety of different types throughout the world, in terms of brewing method and caffeine content; even within the same country methods of preparation and drinking preferences differ significantly. This could partly explain the contrasting results reported in the literature. Hence, we decided to conduct a systematic review with meta-analysis of the available epidemiological studies, both caseecontrol and prospective, in order to evaluate if habitual coffee consumption is associated with an increased risk of CHD.
Methods

Study selection
We conducted a systematic literature search of MEDLINE from 1966, EMBASE from 1990, Science Citation Index from 1994, and the Cochrane Systematic Review Database up to April 2006, to identify studies that examined the association between habitual coffee consumption and CHD, with an analytical designdeither caseecontrol (retrospective or nested) or longitudinal. We used a combined text word and medical subject headings (MeSH) search strategy with the terms 'coffee' and 'caffeine' in combination with 'cardiovascular diseases', 'coronary artery disease', 'coronary heart disease', 'myocardial infarction', and 'acute coronary syndromes'. We included references listed in the retrieved articles as well as in review articles and in meta-analyses. The aim of this study was to evaluate the possible association between coffee consumption and occurrence of CHD, with non-users or the lowest category as a reference. Hence, to be included in the meta-analysis, studies had to provide, as primary or secondary outcome, the association between coffee and CHD, as well as estimates of associations for the different categories of coffee consumption, and full information on study design and participant characteristics.
Our search strategy generated 24 potentially relevant caseecontrol articles [1,2,5,7e12, 21e23, 26,32e42] . Four studies were excluded since they did not contain sufficient information to enable an estimate of risk or its standard error to be calculated for all categories of coffee consumption [1,33e35] . Five studies were excluded because they did not report outcomes of interest for this meta-analysis [36e40], one because it reported only data for decaffeinated coffee consumption [41] , and another study [8] represented the final data from a previous paper [7] , so only the final paper was included. Hence, 13 caseecontrol papers were included in the final analysis [2,5,8e 12,21e23,26,32,42] , incorporating 9487 cases of CHD and 27,747 controls. With regard to cohort prospective studies, we identified 38 potentially relevant studies [3,4,6,13e20,24,25,27,28,33, 43e64] , of which only 10 satisfied the inclusion criteria [4, 14, 17, 20, 24, 25, 27, 28, 43] . Seventeen studies contained insufficient data to enable the associations between different categories of coffee consumption and CHD to be estimated [3,6,15,19,33,44e55] . A further six studies reported outcomes that were not relevant to the present study [56e61] . In addition, the papers by Martin et al. [13] and Hakim et al. [62] were excluded since they studied a population of hypertensives, and two further studies [63, 64] were not included in this review because they included a category other than that of very low consumption as a reference. Finally, papers by Willett et al. [18] and by Grobbee et al. [16] were replaced by the work of Lopez-Garcia et al. [27] , which included updated follow-up analyses deriving from the former two preliminary studies.
Data extraction
All data were independently extracted by two investigators (F.S. and A.M.G.) through use of a standardized data extraction tool, and were entered into separate databases. Data regarding study design, participant characteristics, country of origin, adjustment for potential confounders, measurements of coffee consumption, outcomes, and estimates of associations, were sought from each article. Results were compared, and disagreements were resolved by consensus. In cases in which there was more than one published report on the same population or group of patients, the most recent article was selected for analysis.
Statistical analysis
Data were analysed by using Review Manager (RevMan) software for Windows (version 4.2) by the Cochrane Collaboration, 2003, and STATA (version 8.2). We distinguished four levels of coffee consumption: the highest category of consumption (mainly >4 cups per day, except for Tavani et al. [32] and Kalandidi et al. [10] among caseecontrol studies, and Lindsted et al. [14] among cohort studies, where >3 cups per day was used); the second highest category of coffee consumption (mainly 3e4 cups per day, excluding Jick et al. [2] and Rosenberg et al. [8] among caseecontrol studies, and papers by Klatsky and colleagues [24, 43] among cohort studies, where a range between 1e5 cups per day was used); the third highest category of coffee consumption (mainly 2 cups per day); and the reference category (none or <1 cup per day). Studies not reporting categories of coffee consumption were excluded from each analysis to improve comparability with other studies. Thus, among casee control studies, three studies from the analysis of the second highest category [10, 21, 22] and two from the analysis of the third category [2, 9] were excluded. Similarly, as for cohort prospective studies, two studies from the comparison of the second highest category [14, 17] and one study from the analysis of the third category [17] were excluded. We used the results of the original studies from multivariable models with the most complete adjustment for potential confounders; the confounding variables included in this analysis are shown in Tables 1 and 2 . The analysis was carried out using a random-effects model that accounts for interstudy variation and provides a more conservative estimate than a fixed model. Thus, we calculated random summary odds ratios (OR) and relative risks (RR) with 95% confidence intervals (CI) for caseecontrol and cohort studies, respectively, by using the inverse-variance method. The potential sources of heterogeneity were assessed using the standard chi-square test. In addition, the statistic I 2 was used to investigate heterogeneity by examining the extent of inconsistency across the study results. To examine the source of heterogeneity across studies we conducted sensitivity analyses, according to some characteristics of the studies included in the meta-analysis; i.e. the different region of origin of the studies (Europe/USA), the year of publication (studies published before and after the median year of publication of all the studies combined, i.e. 1995), as well as outcome measures (fatal, non-fatal events), and number of years of follow-up within cohort studies (before and after the median years of follow-up of all the studies combined, i.e. 15 years).
Funnel plots were performed to assess potential publication bias, as suggested by Egger et al. [65] . Moreover, to estimate whether publication bias (if present) would explain the observed associations, we calculated fail-safe numbers that indicated the number of studies with null results that would need to be added to the meta-analysis in order to reduce the overall level of significance of the observed result to that of non-significance [66] .
Results
Caseecontrol studies
Characteristics of the caseecontrol studies included in the meta-analysis are described in Table 1 . The vast majority of these studies had myocardial infarction as the primary outcome. Fig. 1 shows the results of caseecontrol studies for different levels of coffee consumption, compared with the lowest level of coffee consumption. First, we compared the highest category of coffee consumption with the reference category. The summary OR from a random-effect model showed that individuals who consumed a high amount of coffee per day had an increased risk of developing CHD (OR 1.83; 95% CI 1.49e2.24; P < 0.0001) (Fig. 1a) . However, the P value for heterogeneity was 0.02. Studies by Sesso et al. [22] and by Brown et al. [23] contributed substantially to the heterogeneity in this result. Nevertheless, exclusion of these studies from the analysis did not change the significant association found between the highest category of coffee consumption and CHD (OR 2.03; 95% CI 1.77e2.33; P < 0.0001); P for heterogeneity ¼ 0.46. We subsequently compared the second highest category of coffee consumption versus the reference category, showing that the overall effect of a moderately high consumption of coffee remained significantly associated with the occurrence of CHD (OR 1.33; 95% CI 1.04e1.71; P < 0.0001); P for heterogeneity < 0.0001 (Fig. 1b) . Exclusion of the study by Brown et al. [23] , which accounted for the significant heterogeneity demonstrated in this model, did not influence the overall result (OR 1.42; 95% CI 1.18e1.71; P ¼ 0.002); P for heterogeneity ¼ 0.06.
Finally, as the third highest category of coffee consumption (2 cups per day) was analysed, the significant association between coffee consumption and CHD found for the other categories was not present (OR 1.03; 95% CI 0.87e1.21; P ¼ 0.76) (Fig. 1c) . The P for heterogeneity was significant (P ¼ 0.01); however, after exclusion of the study by Brown et al. [23] , which accounted for significant heterogeneity in the model, the results did not change substantially (OR 1.07; 95% CI 0.89e1.29; P ¼ 0.46); P for heterogeneity ¼ 0.06.
Cohort studies
Characteristics of the cohort studies included in the meta-analysis are described in Table 2 . In contrast to caseecontrol studies, many of the cohort prospective studies reported CHD as the primary outcome and involved male subjects.
In 10 cohort studies, including a total of 403,631 participants followed for between 3 and 44 years, the cumulative RR for all cohort studies was 1.16 (95% CI 0.95e1.41; P ¼ 0.14) for the highest category of coffee consumption (Fig. 2a) , thus not showing an association between high coffee consumption and CHD. However, the analysis showed a significant heterogeneity across all studies (P ¼ 0.0008), mainly due to the studies by Klatsky et al. [35] and Lindsted et al. [14] , which accounted for the largest RRs. By excluding these studies from the analysis, the result was confirmed (RR 1.11; 95% CI 0.88e1.41; P ¼ 0.38); P for heterogeneity ¼ 0.08.
We analysed the second highest category of coffee consumption, representing a moderate daily intake of coffee, and the summary RR did not reveal a significant association between coffee consumption and CHD (RR 1.05; 95% CI 0.90e1.22; P ¼ 0.57) (Fig. 2b) . The result was confirmed after exclusion from the analysis of the study by Klag et al. [4] , which accounted for the heterogeneity in the model (RR 1.04; 95% CI 0.89e1.20; P ¼ 0.4).
Finally, we performed the analysis for the third highest category of coffee consumption (2 cups per day), and found that the cumulative RR for all cohort studies was 1.04 (95% CI 0.90e1.19; P ¼ 0.60) (Fig. 2c) . A significant heterogeneity across all studies was reported (P ¼ 0.002); however, after eliminating from the model the study by Lindsted et al. [14] , which accounted for significant heterogeneity, the result did not differ substantially (RR 0.99; 95% CI 0.87e1.12; P ¼ 0.85); P for heterogeneity ¼ 0.34.
Characteristics of the study population
Similar associations for coffee consumption categories among US compared with European casee control and cohort studies were seen (Table 3 ). In contrast, cohort prospective studies published before the median year of publication of all of the studies included, report an association with CHD while those published after the median year. Finally, no significant differences, according to fatal and non-fatal events as well as to the number of years of follow-up within cohort studies, were observed. 
Assessment of publication bias
We explored the potential for publication bias using funnel plots of effect size versus standard error. The plots for all the categories of coffee consumption among caseecontrol studies were broadly symmetrical, consistent with the conclusion that there was no major publication bias, whereas slightly asymmetrical plots for cohort studies were observed. Thus, we calculated the number of studies with null results that would need to be added to the meta-analysis to reduce the overall observed associations to a level of nonsignificance, i.e. the fail-safe number. This was 228 for the highest level of coffee consumption among caseecontrol studies, and nine for the highest category of consumption within cohort studies. Hence, the number was robust for casee control studies only, according to the commonly used criterion that an analysis requires a fail-safe number greater than 5n þ 10 (where n is the original number of studies in the analysis). However, by performing sensitivity analyses among cohort studies, it could be observed that smaller cohort studies published before 1995 are the principle determinants of the low fail-safe number reported.
Decaffeinated coffee
Decaffeinated coffee was examined separately in four caseecontrol studies [5, 8, 9, 22] and three cohort studies [27, 28] included in the meta-analysis. In addition, a paper by La Vecchia et al. [44] eliminated from the previous analysis since it investigated only decaffeinated coffee, was introduced into the present model at this point. Within caseecontrol studies consumption of decaffeinated coffee, in terms of both the highest and lowest categories (>4 cups per day and 2 cups per day, respectively), was not significantly associated with an increased risk of CHD (OR 1.87; 95% CI 0.96e3.46; P ¼ 0.07 and OR 1.05; 95% CI 0.85e 1.29; P ¼ 0.7, respectively); heterogeneity across the studies was also not significant. Similarly, no significant association between decaffeinated coffee consumption and CHD was reported for cohort studies, at both categories of consumption (RR 1.10; 95% CI 0.90e1.34; P ¼ 0.33 and RR 1.00; 95% CI 0.93e1.07; P ¼ 0.90, respectively).
Discussion
The present meta-analysis, performed in 13 casee control and 10 cohort studies, with an overall 1.07 (0.92e1. 25) incorporated population of more than 430,000 subjects and 18,000 CHD cases, shows no clear indication that coffee consumption determines an increased risk of CHD. An association among the highest categories (mainly >2 cups per day) of coffee drinking and CHD within caseecontrol studies has been reported. However, this result was not confirmed among cohort prospective studies with a follow-up period ranging from 3 to 44 years. Nevertheless, it should be noted that among cohort prospective studies, publication bias cannot be excluded because of the low fail-safe number assessed. Finally, decaffeinated coffee, analysed in four caseecontrol and three cohort studies, showed no significant association between both the highest and the third highest categories of coffee consumption and an increased risk of CHD, with respect to the reference category.
During the past three decades, the relationship between coffee drinking and the occurrence of CHD has been assessed in numerous studies, with conflicting results [1e28] . Some studies reported a positive association between coffee intake and CHD [1e14], whereas others did not [15e28], possibly suggesting that the increase in the susceptibility of coronary disease found in previous studies was the result of either an unhealthy lifestyle pattern associated with coffee consumption, or of some detrimental acute effects of coffee intake on CHD-related risk factors. Coffee has been widely investigated for its effects on the cardiovascular system, and the biological plausibility of an increased risk of CHD with a high intake of coffee has been identified through its influence on blood pressure, serum lipids, inflammatory markers, and homocysteinedsome of the most important risk factors for CHD. Administration of coffee has been demonstrated to significantly raise blood pressure in men [67] , but not in women [68] . Moreover, coffee has been reported to raise inflammatory markers and lipid levels, although the effect on lipids is probably influenced by the brewing method, being higher for the boiled compared to the filtered method [36, 69] . Finally, some studies during recent years have reported a significant influence of coffee beverages on plasma levels of homocysteine [70] . On the other hand, a protective effect of coffee consumption on the occurrence of diabetes has been suggested by a recent metaanalysis, which showed a significant inverse association between habitual coffee consumption and the risk of type 2 diabetes [71] . Similarly, coffee consumption has been found to be associated with a reduced risk of chronic liver disease [72] .
Three comprehensive meta-analyses investigating coffee consumption in relation to CVD were published previously, reporting conflicting findings. In 1992, Myers et al. [29] reported that in 11 prospective cohort studies there was no evidence for an association between coffee consumption and the development of CHD; whereas in 1993, Greenland et al. [30] analysed eight caseecontrol and 14 cohort studies, and observed that subjects drinking more than five cups per day had an increased risk of myocardial infarction if compared to non-drinkers, but only among caseecontrol studies. On the other hand, another meta-analysis by Kawachi et al. [31] in 1994 assessing eight caseecontrol and 15 cohort studies, concluded that a moderate-to-high coffee consumption was not significantly associated with an increased risk of coronary death or heart attack. The results of these meta-analyses are in keeping with our findings, since they all show no association between coffee consumption and the occurrence of CHD among cohort prospective studies, whereas a significant association is reported with regard to caseecontrol studies. This divergence of results according to the different type of studies analysed could be ascribed to several factors: first, caseecontrol studies suffer from recall bias, which may explain the positive association shown with the disease as individuals who developed CHD are more likely to over-report coffee intake than are healthy controls. In addition, caseecontrol studies are not likely to include fatal events, whereas cohort studies usually do. This equates to a substantial difference in outcome measures between the two types of studies. Indeed, a recent analysis in the Iowa Women's Study suggests that coffee may even be protective for fatal events, possibly contributing to differences between cohort and caseecontrol studies [28] . Furthermore, caffeine has mainly adverse acute effects on the cardiovascular system, thus explaining the association with CHD found in caseecontrol but not in follow-up studies. Alternatively, some of the discrepancies among studies on coffee and CHD could derive from the complex, heterogeneous, and controversial nature of coffee beverages. There are a wide variety of beverages containing caffeine, and the difference in terms of caffeine content between different types of coffees is extremely significant. In the present meta-analysis we used the estimation of coffee intake as cups consumed per day. This is the unit of measure generally reported in studies considering beverages like coffee and tea. However, there is no standard definition of cup size, and volumes may vary considerably among studies. Similarly, caffeine content is likely to be substantially different among the different kinds of coffee [73] . For instance, espresso coffee, commonly used in Italy, contains 35e45% less caffeine than percolated and boiled coffees, widely used in all other countries. Moreover, the effect of the different types of coffee on blood determinants related to CHD vary considerably: boiled coffee has been found extensively to be associated with an increase in serum cholesterol, whereas no association has been shown for coffee prepared by the filter process [36] . In our meta-analysis we did not find any significant differences when taking into account the regions of origin of the studies or the different types of coffees usually consumed across the different countries. In keeping with our results, a previous meta-analysis by Myers et al. showed no association between the method of coffee preparation and the occurrence of CHD [29] . Another possible explanation for the discrepancies in results could be related to the wide interindividual variability in coffee metabolism present among the population as a whole. Interestingly, it has been reported recently that a genetic variant in the cytochrome P450 1A2 gene, which accounts for approximately 95% of caffeine metabolism, plays an important role in the association between coffee consumption and the occurrence of myocardial infarction [74] . Moreover, it has been shown that subjects carrying this genetic variant had slow caffeine metabolism, and consequently an increased risk for CHD. This finding suggests an environmentalegenetic interaction for coffee consumption, which may further explain the conflicting results of studies investigating coffee intake in relation to CHD. Publication bias is present within cohort prospective studies and is a main limitation in the present meta-analysis, especially considering the low fail-safe numbers obtained. On the other hand, sensitivity analyses performed according to the main characteristics of the studies demonstrated a significant influence of smaller and older studies in determining such bias.
In conclusion, the present meta-analysis indicates that, in general, coffee consumption is not associated with an increased risk of CHD, whereas a significant association of CHD with high consumption of coffee is reported among caseecontrol studies. Furthermore, decaffeinated coffee seems not to be associated with an increased risk of CHD, despite the fact that only a few, limited studies are available where decaffeinated coffee is evaluated separately. The influence of coffee on the health of the people is considered to be of great significance since coffee is one of the most commonly consumed beverages in Western countries. Hence, these results appear of extreme importance in clarifying the relationship between coffee consumption and CHD.
